{"id":249797,"date":"2026-03-31T00:00:00","date_gmt":"2026-03-31T00:00:00","guid":{"rendered":"http:\/\/clarivate.com\/life-sciences-healthcare\/report\/biosbi0020-biopharma-biosimilars-forecast-forecast-methodology-and\/"},"modified":"2026-04-22T05:09:26","modified_gmt":"2026-04-22T05:09:26","slug":"biosbi0020-2026-biopharma-biosimilars-forecast-forecast-methodology-and-general-market-assumptions","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/biosbi0020-2026-biopharma-biosimilars-forecast-forecast-methodology-and-general-market-assumptions\/","title":{"rendered":"Biosimilars &#8211; Forecast &#8211; Forecast Methodology and General Market Assumptions"},"content":{"rendered":"<p>In 2024, sales of branded biologics for oncology (except G-CSFs), immunology, endocrinology, ophthalmology, neurology, osteoporosis, and respiratory indications exceeded $160\u00a0billion in the major pharmaceutical markets under study (United States, <abbr title=\"France, Germany, Italy, Spain, UK\">EU5<\/abbr>, and Japan). Sales of biosimilars in these therapy areas and countries totaled approximately $19\u00a0billion. Throughout our 2024-2034 forecast period, increasing numbers of branded biologics are set to lose patent protection, and we expect biosimilars to enter the market and erode patient share and drug prices, generating\u00a0savings of approximately $37 billion\u00a0to healthcare systems. We present our forecasts for key reference brands and their biosimilars by therapeutic area, molecule, and country \/ region.<\/p>\n","protected":false},"template":"","class_list":["post-249797","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-product-biosimilars","biopharma-date-2609"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/249797","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":5,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/249797\/revisions"}],"predecessor-version":[{"id":578223,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/249797\/revisions\/578223"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=249797"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}